The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer

Notwithstanding the positive clinical impact of endocrine therapies in estrogen receptor-alpha (ERα)-positive breast cancer, de novo and acquired resistance limits the therapeutic lifespan of existing drugs. Taking the position that resistance is nearly inevitable, we undertook a study to identify a...

Descripción completa

Detalles Bibliográficos
Autores principales: Cocce, Kimberly J., Jasper, Jeff S., Desautels, Taylor K., Everett, Logan, Wardell, Suzanne, Westerling, Thomas, Baldi, Robert, Wright, Tricia M., Tavares, Kendall, Yllanes, Alex, Bae, Yeeun, Blitzer, Jeremy T., Logsdon, Craig, Rakiec, Daniel P., Ruddy, David A., Jiang, Tiancong, Broadwater, Gloria, Hyslop, Terry, Hall, Allison, Laine, Muriel, Phung, Linda, Greene, Geoffrey L., Martin, Lesley-Ann, Pancholi, Sunil, Dowsett, Mitch, Detre, Simone, Marks, Jeffrey R., Crawford, Gregory E., Brown, Myles, Norris, John D., Chang, Ching-yi, McDonnell, Donald P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874102/
https://www.ncbi.nlm.nih.gov/pubmed/31644911
http://dx.doi.org/10.1016/j.celrep.2019.09.032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874102/
https://www.ncbi.nlm.nih.gov/pubmed/31644911
http://dx.doi.org/10.1016/j.celrep.2019.09.032

Ejemplares similares